

CERTIFICATE OF MAILING

I hereby certify that this TRANSMITTAL is being deposited with the U.S. Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on this 16th day of August, 2002.

Typed or Printed name of person signing this certificate:
Wendy A. Frick



Signed: Wendy A. Frick

AUG 21 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:
Hazen, et al.

Serial No.: 10/039,753

Filed: January 2, 2002

For: **MYELOPEROXIDASE, A RISK
INDICATOR FOR CARDIOVASCULAR
DISEASE**

COPY OF PAPERS
ORIGINALLY FILED

24024
PATENT TRADEMARK OFFICE

RECEIVED

SEP 11 2002

TECH CENTER 1600/2900
PATENT

PATENT

Examiner: Not yet assigned

Art Unit: 3736

Attorney Docket No.: 26473/04177

RECEIVED

AUG 23 2002

TECHNOLOGY CENTER 43700

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
Sir:

Transmitted herewith are the following:

1. Supplemental Information Disclosure Statement;
2. Form PTO-1449;
3. 7 References; and
4. A Return Receipt Postcard.

It is believed that no further fee is required relating to the filing of this Supplemental Information Disclosure Statement. If this is not the case, the Patent Office is hereby authorized to charge any related fee to Deposit Account No. 03-0172. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date: August 16, 2002

By: Pamela A. Docherty
Pamela A. Docherty, Reg. No. 40,591
(216) 622-8416

CERTIFICATION

- Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this statement.
- This information disclosure statement is being filed within three months of the filing of the within application and/or prior to a first Office Action on the merits being received.

PETITION

- Applicants hereby request consideration of the attached information.


DEPOSIT ACCOUNT

- A check is attached in the amount of \$ _____ required under 37 § 1.17(p).
- It is not believed that any fee is required relating to the filing of this information disclosure statement. If this is not the case, the patent office is hereby authorized to charge any related fee to **Deposit Account No. 03-0172**.

Respectfully submitted,

Date: August 16, 2002

By:


Pamela A. Docherty, Reg. No. 40,591
(216) 622-8416

RECEIVED

COPY OF PAPERS
ORIGINALLY FILED

SEP 11 2002

Page 1 of 1

TECH CENTER 1600/2900

Subst. Form PTO-1449	Atty. Docket No.: 26473/04177	Serial No.: 10/039,753
APPLICANT'S INFORMATION DISCLOSURE STATEMENT		
	Applicant: Hazen, et al. Filing Date: January 2, 2002	Group: 3736

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
	AA	5,122,534	June 16, 1992	Loose, et al.			Jul. 10, 1991
O P E	AB	5,889,042	March 30, 1999	MacLean, et al.			Feb. 21, 1997
JO	AC						
PATENT & TRADEMARK OFFICE	AD						

AUG 21 2002

FOREIGN PATENT DOCUMENTS

Initial*		Document No.	Date	Country	Class	Subcl.	Translati n?
	AE						
	AF						
	AG						RECEIVED
	AH						
	AI						AUG 23 2002

OTHER PRIOR ART

TECHNOLOGY CENTER 1600/2900

AJ	International Search Report dated July 31, 2002.
AK	“Oxidized LDL and HDL: antagonists in atherosclerosis” by Mertens, et al., <i>FASEB J.</i> , 15, 2073-2084 (2001).
AL	“Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species” by Podrez, et al., <i>J. Clin. Invest.</i> 105:1095-1108 (2000).
AM	“Inhibition of Adhesion Molecules Markedly Ameliorates Cytokine-Induced Sustained Myocardial Dysfunction in Dogs <i>in vivo</i> ” by Momii, et al., <i>J. Mol. Cell. Cardiol.</i> 30, 2637-2650 (1998).
AN	“Supplementation with Tetrahydrobiopterin Suppresses the Development of Hypertension in Spontaneously Hypertension Rats” by Hong, et al., <i>Hypertension</i> , 2001; 38:1044-1048.
AO	
AP	
AQ	
AR	

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.